Pfizer Inc and BioNTech SE said on Wednesday that real-world data from Israel suggests that their Covid-19 vaccine is 94 per cent effective in preventing asymptomatic infections, meaning the vaccine could significantly reduce transmission.
The companies also said the latest analysis of the Israeli data shows the vaccine was 97 per cent effective in preventing symptomatic disease, severe disease and death.
This is basically in line with the 95 per cent efficacy Pfizer and BioNTech reported from the vaccine's late-stage clinical trial in December.
The analysis also shows real-world evidence of the vaccine's effectiveness against a highly infectious variant of Covid-19 first discovered in Britain, known as B.1.1.7. More than 80 per cent of the tested specimens when the analysis was conducted were variant B.1.1.7.
There was only a limited number of infections in Israel caused by the so-called South African variant - known as B.1.351 - so they were not able to evaluate vaccine effectiveness against this variant.
Leading the way
Israel is leading the world in its vaccination roll out, due in part to an agreement to share data with Pfizer and BioNTech.
As of Wednesday, around 55 per cent of its nine million population had been given at least one dose of the Pfizer/BioNTech Covid-19 vaccine, according to Health Ministry data, and 43 per cent have received both doses.
According to the analysis, unvaccinated individuals were 44 times more likely to develop symptomatic Covid-19 and 29 times more likely to die from Covid-19 than those who had received the vaccine.
The data, collected between January 17th and March 6th, has not yet been peer reviewed.
Israel's health ministry previously found the Pfizer vaccine developed with Germany's BioNTech reduces infection, including in asymptomatic cases, by 89.4 per cent and in symptomatic cases by 93.7 per cent. That was in data collected between January 17th and February 6th.
